TOP TIERMARKET NEWSWIRE
Movers explained · October 6, 2026

Why Is ARRIVENT BIOPHARMA I (AVBP) Stock Down Today?

By the Top Tier Newswire AI Desk · reviewed against 10 wire stories

ARRIVENT BIOPHARMA I (AVBP) is down -57.10% in the latest session. Our newswire has captured 10 stories on AVBP across 8 sources in the last 36 hours, with AI sentiment reading bearish (avg 31/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

The written analysis for AVBP publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.

AVBP by the numbers

Last: $12.21Session: -57.10%7 sessions: -5.45%Coverage: 10 stories / 8 sourcesAI sentiment: 31/100 (bearish)
AVBP · today's session (5-min) · -57.87% vs prior close · updated 9:33 AM ET
$9.41$19.60$29.79prev close $28.46$11.997:00 AM7:37 AM8:15 AM8:52 AM9:30 AM7:00 AM · $28.407:05 AM · $28.407:45 AM · $28.708:30 AM · $10.508:35 AM · $11.158:40 AM · $12.008:45 AM · $12.398:50 AM · $11.868:55 AM · $11.669:00 AM · $11.479:05 AM · $11.749:10 AM · $12.009:15 AM · $11.909:20 AM · $11.899:25 AM · $12.099:30 AM · $11.99
AI sentiment, last 36h · averaged over 10 stories · 31/100 bearish
AI sentiment 31/100 (bearish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agonowStockTitan · sentiment 63 · ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLCStockTitan · 63ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in Firs…SEC 8-K · sentiment 50 · ArriVent BioPharma, Inc. (AVBP) files 8-KSEC 8-K · 50ArriVent BioPharma, Inc. (AVBP) files 8-KTipRanks · sentiment 28 · ArriVent’s FURVENT Phase 3 Trial Misses Primary EndpointTipRanks · 28ArriVent’s FURVENT Phase 3 Trial Misses Primary EndpointInvesting.com Markets · sentiment 22 · ArriVent stock tumbles 60% after trial misses primary endpointInvesting.com Markets · 22ArriVent stock tumbles 60% after trial misses primary endpointInvesting.com Markets · sentiment 34 · Why is Arrivent Biopharma stock collapsing today?Investing.com Markets · 34Why is Arrivent Biopharma stock collapsing today?MarketChameleon · sentiment 28 · AVBP Shares React After FURVENT Misses Primary PFS Endpoint Despite Higher Confirmed Response Rate at 240 mg October 6, 2026MarketChameleon · 28AVBP Shares React After FURVENT Misses Primary PFS Endpoint Despite Higher Confirmed Resp…Reuters · sentiment 18 · ArriVent's oral lung cancer therapy fails late-stage trial, shares plungeReuters · 18ArriVent's oral lung cancer therapy fails late-stage trial, shares plungeThe Fly · sentiment 28 · ArriVent says Phase 3 firmonertinib trial did not meet endpointThe Fly · 28ArriVent says Phase 3 firmonertinib trial did not meet endpointThe Fly · sentiment 18 · ArriVent sinks 60% to $11.50 after Phase 3 study missThe Fly · 18ArriVent sinks 60% to $11.50 after Phase 3 study missSeeking Alpha · sentiment 18 · ArriVent plunges as lead asset fails in late-stage cancer trialSeeking Alpha · 18ArriVent plunges as lead asset fails in late-stage cancer trial
38m agoSeeking AlphaBEARISH 18Product/PR

ArriVent plunges as lead asset fails in late-stage cancer trial

ArriVent BioPharma (AVBP) stock plunges 50% as lead asset fails in a late-stage trial for a type of lung cancer. Read more here.

1h agoThe FlyBEARISH 18Earnings

ArriVent sinks 60% to $11.50 after Phase 3 study miss

1h agoThe FlyBEARISH 28Product/PR

ArriVent says Phase 3 firmonertinib trial did not meet endpoint

1h agoReutersBEARISH 18Product/PR

ArriVent's oral lung cancer therapy fails late-stage trial, shares plunge

1h agoMarketChameleonBEARISH 28Earnings

AVBP Shares React After FURVENT Misses Primary PFS Endpoint Despite Higher Confirmed Response Rate at 240 mg October 6, 2026

ArriVent BioPharma (AVBP) said its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion-mutant NSCLC did not meet the primary endpoint of PFS by blinded independent central review. The company highlighted secondary endpoint signals, including higher confirmed response rates at 240 mg and more favorable investigator-assessed PFS, while reporting no new safety signals and broadly similar high-grade TEAE rates across arms.

1h agoInvesting.com MarketsBEARISH 34General

Why is Arrivent Biopharma stock collapsing today?

Why is Arrivent Biopharma stock collapsing today?

1h agoInvesting.com MarketsBEARISH 22Earnings

ArriVent stock tumbles 60% after trial misses primary endpoint

ArriVent stock tumbles 60% after trial misses primary endpoint

2h agoTipRanksBEARISH 28Product/PR

ArriVent’s FURVENT Phase 3 Trial Misses Primary Endpoint

ArriVent BioPharma, Inc. ( ($AVBP) ) has provided an announcement. On October 6, 2026, ArriVent reported that its global Phase 3 FURVENT trial of firmonertinib as a...

2h agoSEC 8-KNEUTRAL 50General

ArriVent BioPharma, Inc. (AVBP) files 8-K

Filed: 2026-10-06 AccNo: 0001104659-26-113898 Size: 229 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

2h agoStockTitanBULLISH 63Product/PR

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

Frequently asked questions

Why is AVBP stock down today?

ARRIVENT BIOPHARMA I (AVBP) is down -57.10% in the latest session. Our newswire has captured 10 stories on AVBP across 8 sources in the last 36 hours, with AI sentiment reading bearish (avg 31/100). The most recent driver: "ArriVent plunges as lead asset fails in late-stage cancer trial" (Seeking Alpha).

Is AVBP a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of AVBP coverage reads 31/100 over 10 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.

More moves explained today

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on AVBP: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.